Stopping Pharma’s Ripoffs and Drug Savings For All Act

H.R. 1717: Interagency Patent Coordination and Improvement Act of 2023 H.R. 4370: PREVAIL Act - Provisions related to the PTAB H.R. 4692: Increasing Prescription Drug Competition Act - Patent-related policy issues H.R. 5429: Medication Affordability and Patent Integrity Act H.R. 5475: Prohibiting Adversarial Patents Act of 2023 H.R. 6275: Protecting Consumer Access to Generic Drugs Act of 2023 - Patent-related policy issues H.R. 6436: Stopping Pharmas Ripoffs and Drug Savings For All Act - Patent-related policy issues H.R. 6684: Improving Efficiency to Increase Competition Act - Patent-related policy issues H.R. 6986: To address patent thickets. - Provisions related to patents S. 79: Interagency Patent Coordination and Improvement Act of 2023 S. 142: Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements S. 150: Affordable Prescriptions for Patients Act of 2023 - Provisions related to intellectual property and patents S. 574: Increasing Prescription Drug Competition Act - Patent-related policy issues S. 2140: Patent Eligibility Restoration Act of 2023 - Provisions related to patents S. 2220: PREVAIL Act - Provisions related to the PTAB S. 2780: Medication Affordability and Patent Integrity Act S. 3569: Improving Efficiency to Increase Competition Act S. 3583: A bill to address patent thickets. - Provisions related to patents Biopharmaceutical innovation and patent policy issues Bayh-Dole march-in rights policy issues Request for Information Regarding the Draft Interagency Guidance Framework for considering the Exercise of March-In Rights (Docket No.: 230831-0207) Patent thicket policy issues Patent use codes policy issues AI patent policy issues

Client expense: $6,880,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.4875/H.R. 9551, the NO FAKES Act of 2023 S. 2780, the Medication Affordability and Patent Integrity Act H.R. 9455/ S. the IDEA Act H.R. 9211/S. 4840, the RESTORE Patent Rights Act of 2024 S. 5160, Sharing of information with respect to suspected violations of intellectual property rights. H.R. 8134, the Restoring America's Leadership in Innovation Act of 2024 (RALIA) H.R. 8132, Balancing Incentives Act of 2024 H.R. 7913, Generative AI Copyright Disclosure Act of 2024 H.R. 6684/S. 3569, Improving Efficiency to Increase Competition Act H.R. 5475, Prohibiting Adversarial Patents Act of 2023 H.R. 6436, Stopping Pharmas Ripoffs and Drug Savings For All Act S, 2934, the SHOP SAFE Act of 2023 H.R. 5475, Prohibiting Adversarial Patents Act of 2023 S. 2566, the American IP Defense and Enforcement Advancement Act H.R. 9474/S. 2140, Patent Eligibility Restoration Act of 2023 S. 2220/H.R. 4370, Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act H.R. 1707, the SMART Act S. 1128, Ensuring Access to Generic Medications Act S.835/H.R.1631, the Pro Codes Act S. 746/H.R. 1505, the No Stolen Trademarks Honored in America Act S. 574, Increasing Prescription Drug Competition Act S. 253/H.R. 791, the American Music Fairness Act of 2023 S. 153, the Fair Trade with China Enforcement Act S. 150, the Affordable Prescriptions for Patients Act S. 113 Pricing for the People Act S. 79/H.R. 1717, the Interagency Patent Coordination and Improvement Act of 2023. S. 42, Prescription Preserve Access to Affordable Generics and Biosimilars Act H.R.2594 - To control the export to the People's Republic of China of certain technology and intellectual property important to the national interest of the United States, and for other purposes. H.R. 2070 - To provide for a limitation on availability of funds for Executive Office of the President, Intellectual Property Enforcement Coordinator for fiscal year 2024 H.R. 1016, the Stop Chinas IP Theft Act H.R. 906 , the REPAIR Act H.R. 576, the Copyright Clause Restoration Act of 2023 Issues related to USPTO operations Issues related to international patent harmonization Issues related to patent subject matter eligibility Issues related to Copyright Office Modernization Issues related to the WTO TRIPs Waiver Request

H.R. 1717: Interagency Patent Coordination and Improvement Act of 2023 H.R. 4370: PREVAIL Act - Provisions related to the PTAB H.R. 4692: Increasing Prescription Drug Competition Act - Patent-related policy issues H.R. 5429: Medication Affordability and Patent Integrity Act H.R. 5475: Prohibiting Adversarial Patents Act of 2023 H.R. 6275: Protecting Consumer Access to Generic Drugs Act of 2023 - Patent-related policy issues H.R. 6436: Stopping Pharmas Ripoffs and Drug Savings For All Act - Patent-related policy issues H.R. 6684: Improving Efficiency to Increase Competition Act - Patent-related policy issues H.R. 6986: To address patent thickets. - Provisions related to patents S. 79: Interagency Patent Coordination and Improvement Act of 2023 S. 142: Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements S. 150: Affordable Prescriptions for Patients Act of 2023 - Provisions related to intellectual property and patents S. 574: Increasing Prescription Drug Competition Act - Patent-related policy issues S. 2140: Patent Eligibility Restoration Act of 2023 - Provisions related to patents S. 2220: PREVAIL Act - Provisions related to the PTAB S. 2780: Medication Affordability and Patent Integrity Act S. 3569: Improving Efficiency to Increase Competition Act S. 3583: A bill to address patent thickets. - Provisions related to patents Biopharmaceutical innovation and patent policy issues Bayh-Dole march-in rights policy issues Request for Information Regarding the Draft Interagency Guidance Framework for considering the Exercise of March-In Rights (Docket No.: 230831-0207) Patent thicket policy issues Patent use codes policy issues AI patent policy issues

Client expense: $1,510,000 · Firm income: Not reported

H.R. 1717: Interagency Patent Coordination and Improvement Act of 2023 H.R. 4370: PREVAIL Act - Provisions related to the PTAB H.R. 4692: Increasing Prescription Drug Competition Act - Patent-related policy issues H.R. 5429: Medication Affordability and Patent Integrity Act H.R. 5475: Prohibiting Adversarial Patents Act of 2023 H.R. 6275: Protecting Consumer Access to Generic Drugs Act of 2023 - Patent-related policy issues H.R. 6436: Stopping Pharmas Ripoffs and Drug Savings For All Act - Patent-related policy issues H.R. 6684: Improving Efficiency to Increase Competition Act - Patent-related policy issues H.R. 6986: To address patent thickets. - Provisions related to patents S. 79: Interagency Patent Coordination and Improvement Act of 2023 S. 142: Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements S. 150: Affordable Prescriptions for Patients Act of 2023 - Provisions related to intellectual property and patents S. 574: Increasing Prescription Drug Competition Act - Patent-related policy issues S. 2140: Patent Eligibility Restoration Act of 2023 - Provisions related to patents S. 2220: PREVAIL Act - Provisions related to the PTAB S. 2780: Medication Affordability and Patent Integrity Act S. 3569: Improving Efficiency to Increase Competition Act S. 3583: A bill to address patent thickets. - Provisions related to patents Biopharmaceutical innovation and patent policy issues Bayh-Dole march-in rights policy issues Request for Information Regarding the Draft Interagency Guidance Framework for considering the Exercise of March-In Rights (Docket No.: 230831-0207) Patent thicket policy issues Patent use codes policy issues AI patent policy issues

Client expense: $6,960,000 · Firm income: Not reported

H.R. 8134, the Restoring America's Leadership in Innovation Act of 2024 (RALIA) H.R. 8132, Balancing Incentives Act of 2024 H.R. 7913, Generative AI Copyright Disclosure Act of 2024 H.R. 6684/S. 3569, Improving Efficiency to Increase Competition Act H.R. 5475, Prohibiting Adversarial Patents Act of 2023 H.R. 6436, Stopping Pharmas Ripoffs and Drug Savings For All Act S, 2934, the SHOP SAFE Act of 2023 H.R. 5475, Prohibiting Adversarial Patents Act of 2023 S. 2566, the American IP Defense and Enforcement Advancement Act S. 2140, Patent Eligibility Restoration Act of 2023 S. 2220/H.R. 4370, Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act H.R. 1707, the SMART Act S. 1128, Ensuring Access to Generic Medications Act S.835/H.R.1631, the Pro Codes Act S. 746/H.R. 1505, the No Stolen Trademarks Honored in America Act S. 574, Increasing Prescription Drug Competition Act S. 253/H.R. 791, the American Music Fairness Act of 2023 S. 153, the Fair Trade with China Enforcement Act S. 150, the Affordable Prescriptions for Patients Act S. 113 Pricing for the People Act S. 79/H.R. 1717, the Interagency Patent Coordination and Improvement Act of 2023. S. 42, Prescription Preserve Access to Affordable Generics and Biosimilars Act H.R.2594 - To control the export to the People's Republic of China of certain technology and intellectual property important to the national interest of the United States, and for other purposes. H.R. 2070 - To provide for a limitation on availability of funds for Executive Office of the President, Intellectual Property Enforcement Coordinator for fiscal year 2024 H.R. 1016, the Stop Chinas IP Theft Act H.R. 906 , the REPAIR Act H.R. 576, the Copyright Clause Restoration Act of 2023 Issues related to USPTO operations Issues related to international patent harmonization Issues related to patent subject matter eligibility Issues related to Copyright Office Modernization Issues related to the WTO TRIPs Waiver Request

H.R. 1717: Interagency Patent Coordination and Improvement Act of 2023 H.R. 4370: PREVAIL Act - Provisions related to the PTAB H.R. 4692: Increasing Prescription Drug Competition Act - Patent-related policy issues H.R. 5429: Medication Affordability and Patent Integrity Act H.R. 5475: Prohibiting Adversarial Patents Act of 2023 H.R. 6275: Protecting Consumer Access to Generic Drugs Act of 2023 - Patent-related policy issues H.R. 6436: Stopping Pharmas Ripoffs and Drug Savings For All Act - Patent-related policy issues H.R. 6684: Improving Efficiency to Increase Competition Act - Patent-related policy issues H.R. 6986: To address patent thickets - Provisions related to patents S. 79: Interagency Patent Coordination and Improvement Act of 2023 S. 142: Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements S. 150: Affordable Prescriptions for Patients Act of 2023 - Provisions related to intellectual property and patents S. 574: Increasing Prescription Drug Competition Act - Patent-related policy issues S. 2140: Patent Eligibility Restoration Act of 2023 - Provisions related to patents S. 2220: PREVAIL Act - Provisions related to the PTAB S. 2780: Medication Affordability and Patent Integrity Act S. 3583: A bill to address patent thickets - Provisions related to patents Biopharmaceutical innovation and patent policy issues Bayh-Dole march-in rights policy issues Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (Docket No.: 230831-0207) Patent thicket policy issues Patent use codes policy issues AI patent policy issues

Client expense: $820,000 · Firm income: Not reported

H.R. 1717: Interagency Patent Coordination and Improvement Act of 2023 H.R. 4370: PREVAIL Act - Provisions related to the PTAB H.R. 4692: Increasing Prescription Drug Competition Act - Patent-related policy issues H.R. 5429: Medication Affordability and Patent Integrity Act H.R. 5475: Prohibiting Adversarial Patents Act of 2023 H.R. 6275: Protecting Consumer Access to Generic Drugs Act of 2023 - Patent-related policy issues H.R. 6436: Stopping Pharmas Ripoffs and Drug Savings For All Act - Patent-related policy issues H.R. 6684: Improving Efficiency to Increase Competition Act - Patent-related policy issues H.R. 6986: To address patent thickets - Provisions related to patents S. 79: Interagency Patent Coordination and Improvement Act of 2023 S. 142: Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements S. 150: Affordable Prescriptions for Patients Act of 2023 - Provisions related to intellectual property and patents S. 574: Increasing Prescription Drug Competition Act - Patent-related policy issues S. 2140: Patent Eligibility Restoration Act of 2023 - Provisions related to patents S. 2220: PREVAIL Act - Provisions related to the PTAB S. 2780: Medication Affordability and Patent Integrity Act S. 3583: A bill to address patent thickets - Provisions related to patents Biopharmaceutical innovation and patent policy issues Bayh-Dole march-in rights policy issues Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (Docket No.: 230831-0207) Patent thicket policy issues Patent use codes policy issues AI patent policy issues

Client expense: $9,600,000 · Firm income: Not reported

H.R. 6684/S. 3569, Improving Efficiency to Increase Competition Act H.R. 5475, Prohibiting Adversarial Patents Act of 2023 H.R. 6436, Stopping Pharmas Ripoffs and Drug Savings For All Act S, 2934, the SHOP SAFE Act of 2023 H.R. 5475, Prohibiting Adversarial Patents Act of 2023 S. 2566, the American IP Defense and Enforcement Advancement Act S. 2140, Patent Eligibility Restoration Act of 2023 S. 2220/H.R. 4370, Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act H.R. 1707, the SMART Act S. 1128, Ensuring Access to Generic Medications Act S.835/H.R.1631, the Pro Codes Act S. 746/H.R. 1505, the No Stolen Trademarks Honored in America Act S. 574, Increasing Prescription Drug Competition Act S. 253/H.R. 791, the American Music Fairness Act of 2023 S. 153, the Fair Trade with China Enforcement Act S. 150, the Affordable Prescriptions for Patients Act S. 113 Pricing for the People Act S. 79/H.R. 1717, the Interagency Patent Coordination and Improvement Act of 2023. S. 42, Prescription Preserve Access to Affordable Generics and Biosimilars Act H.R.2594 - To control the export to the People's Republic of China of certain technology and intellectual property important to the national interest of the United States, and for other purposes. H.R. 2070 - To provide for a limitation on availability of funds for Executive Office of the President, Intellectual Property Enforcement Coordinator for fiscal year 2024 H.R. 1016, the Stop Chinas IP Theft Act H.R. 906 , the REPAIR Act H.R. 576, the Copyright Clause Restoration Act of 2023 Issues related to USPTO operations Issues related to international patent harmonization Issues related to patent subject matter eligibility Issues related to Copyright Office Modernization Issues related to the WTO TRIPs Waiver Request

H.R. 1717: Interagency Patent Coordination and Improvement Act of 2023 H.R. 4370: PREVAIL Act - Provisions related to the PTAB H.R. 4692: Increasing Prescription Drug Competition Act - Patent-related policy issues H.R. 5429: Medication Affordability and Patent Integrity Act H.R. 5475: Prohibiting Adversarial Patents Act of 2023 H.R. 6275: Protecting Consumer Access to Generic Drugs Act of 2023 - Patent-related policy issues H.R. 6436: Stopping Pharmas Ripoffs and Drug Savings For All Act - Patent-related policy issues H.R. 6684: Improving Efficiency to Increase Competition Act - Patent-related policy issues S. 79: Interagency Patent Coordination and Improvement Act of 2023 S. 142: Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements S. 150: Affordable Prescriptions for Patients Act of 2023 - Provisions related to intellectual property and patents S. 574: Increasing Prescription Drug Competition Act - Patent-related policy issues S. 2140: Patent Eligibility Restoration Act of 2023 - Provisions related to patents S. 2220: PREVAIL Act - Provisions related to the PTAB S. 2780: Medication Affordability and Patent Integrity Act Biopharmaceutical innovation and patent policy issues Bayh-Dole march-in rights policy issues H.R. 4692: Increasing Prescription Drug Competition Act - Patent-related policy issues Biopharmaceutical innovation and patent policy issues Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (Docket No.: 230831-0207) Patent thicket policy issues Patent use codes policy issues

Client expense: $1,500,000 · Firm income: Not reported

H.R. 1717: Interagency Patent Coordination and Improvement Act of 2023 H.R. 4370: PREVAIL Act - Provisions related to the PTAB H.R. 4692: Increasing Prescription Drug Competition Act - Patent-related policy issues H.R. 5429: Medication Affordability and Patent Integrity Act H.R. 5475: Prohibiting Adversarial Patents Act of 2023 H.R. 6275: Protecting Consumer Access to Generic Drugs Act of 2023 - Patent-related policy issues H.R. 6436: Stopping Pharmas Ripoffs and Drug Savings For All Act - Patent-related policy issues H.R. 6684: Improving Efficiency to Increase Competition Act - Patent-related policy issues S. 79: Interagency Patent Coordination and Improvement Act of 2023 S. 142: Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements S. 150: Affordable Prescriptions for Patients Act of 2023 - Provisions related to intellectual property and patents S. 574: Increasing Prescription Drug Competition Act - Patent-related policy issues S. 2140: Patent Eligibility Restoration Act of 2023 - Provisions related to patents S. 2220: PREVAIL Act - Provisions related to the PTAB S. 2780: Medication Affordability and Patent Integrity Act Biopharmaceutical innovation and patent policy issues Bayh-Dole march-in rights policy issues Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (Docket No.: 230831-0207) Patent thicket policy issues Patent use codes policy issues

Client expense: $6,430,000 · Firm income: Not reported

H.R. 5475, Prohibiting Adversarial Patents Act of 2023 H.R. 6436, Stopping Pharmas Ripoffs and Drug Savings For All Act S, 2934, the SHOP SAFE Act of 2023 H.R. 5475, Prohibiting Adversarial Patents Act of 2023 S. 2566, the American IP Defense and Enforcement Advancement Act S. 2140, Patent Eligibility Restoration Act of 2023 S. 2220/H.R. 4370, Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act H.R. 1707, the SMART Act S. 1128, Ensuring Access to Generic Medications Act S.835/H.R.1631, the Pro Codes Act S. 746/H.R. 1505, the No Stolen Trademarks Honored in America Act S. 574, Increasing Prescription Drug Competition Act S. 253/H.R. 791, the American Music Fairness Act of 2023 S. 153, the Fair Trade with China Enforcement Act S. 150, the Affordable Prescriptions for Patients Act S. 113 Pricing for the People Act S. 79/H.R. 1717, the Interagency Patent Coordination and Improvement Act of 2023. S. 42, Prescription Preserve Access to Affordable Generics and Biosimilars Act H.R.2594 - To control the export to the People's Republic of China of certain technology and intellectual property important to the national interest of the United States, and for other purposes. H.R. 2070 - To provide for a limitation on availability of funds for Executive Office of the President, Intellectual Property Enforcement Coordinator for fiscal year 2024 H.R. 1016, the Stop Chinas IP Theft Act H.R. 906 , the REPAIR Act H.R. 576, the Copyright Clause Restoration Act of 2023 Issues related to USPTO operations Issues related to international patent harmonization Issues related to patent subject matter eligibility Issues related to Copyright Office Modernization Issues related to the WTO TRIPs Waiver Request

Client expense: Not reported · Firm income: Not reported